Peptilogics
Manufacturing · Pennsylvania, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2730 Sidney St Ste 300, Pittsburgh, Penn...Phone Number
(412) 643-4924Website
www.peptilogics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Peptilogics
Peptilogics is developing therapeutics for orthopedic hardware-related infections. The company's lead candidate, zaloganan (PLG0206), is an investigational treatment for prosthetic joint infections currently in clinical development.Explore more
Peptilogics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Peptilogics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Peptilogics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Peptilogics
Product Launch: Get notified when Peptilogics launches new products
Peptilogics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Peptilogics recently announced quarterly report
Check out if Peptilogics is spiking on competitors!
Check if Peptilogics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Peptilogics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Peptilogics
Find 3 more new buyers
Compare Similar Companies to Peptilogics
Compare insights from companies similar to Peptilogics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Peptilogics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Peptilogics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Peptilogics.
Peptilogics financials insights
Gather financial insights about Peptilogics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$5.5M
2020
Unspecified
$12.2M
2025
Series B
$113.4M
Peptilogics Tech Stack
A closer look at the technologies used by Peptilogics
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Person-Based
Person-Based
Peptilogics News & Media
Peptilogics CTO Nick Nystrom Wants to Hasten Drug Design Through Supercomputing
Nystrom is bringing AI into biotech to create safer and more effective medicines.Peptilogics Reports Positive 180-Day Top-Line Interim Data From Phase 1B Trial of PLG0206 in Patients With Periprosthetic Joint Infection (PJI)
PITTSBURGH--(BUSINESS WIRE)--Peptilogics, a clinical-stage biotechnology company, today announced new top-line interim data for PLG0206 in periprosthetic joint infection (PJI) patients from their ongoing Phase 1b trial. At 180-days following treatment with PLG0206 administered during a DAIR (Debridement, Antibiotics, and Implant Retention) surgery, no treatment-related serious adverse events were reported in either cohort. One recurrence was observed in the trial (one of 14 patients, 7%), whichPeptilogics Reports Positive 90-Day Top Line Interim Data From Phase 1b Trial of PLG0206 in Patients With Periprosthetic Joint Infection (PJI)
PITTSBURGH--(BUSINESS WIRE)--Peptilogics, a clinical-stage biotechnology company, today announced top-line interim data of PLG0206 in PJI patients from their ongoing Phase 1b trial. At 90 days post-Debridement, Antibiotics, and Implant Retention (DAIR) surgery, there were no treatment-related adverse events reported in the low-dose cohort. Additionally, zero infection recurrences were observed in this subset of patients compared to 44% recurrence rate in historical controls as shown by Zhu, et.Peptilogics Completes Phase 1b Trial Enrollment and Will Present Interim Top-line Safety and Tolerability Data of PLG0206 in Patients Undergoing DAIR for the Treatment of Periprosthetic Joint Infection After a Total Knee Arthroplasty at ECCMID 2023
PITTSBURGH--(BUSINESS WIRE)--Peptilogics, a clinical stage biotechnology company, has completed the enrollment of a Phase 1b trial for PLG0206 in patients undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for treatment of a Periprosthetic Joint Infection (PJI) occurring after Total Knee Arthroplasty (TKA). The trial is an open-label dose-escalating study with two dose cohorts of seven patients each compared to historical controls. Peptilogics will present the interim top-line da
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Peptilogics
Sign Up For FreeTo access detailed company insights
Peptilogics is developing therapeutics for orthopedic hardware-related infections. The company's lead candidate, zaloganan (PLG0206), is an investigational treatment for prosthetic joint infections currently in clinical development.... Read More
